Alport syndrome

Revision as of 20:51, 30 July 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search

Template:DiseaseDisorder infobox Template:Search infobox For patient information on this page, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Synonyms and keywords: Hereditary nephritis; hemorrhagic familial nephritis; X-linked nephropathy and deafness

Overview

Alport syndrome is a genetic condition characterized by the progressive loss of kidney, eye and ear functioning. The disorder originates from mutations in critical genes involved in the structure of basement membranes. The presence of blood in the urine (hematuria) is almost always found in this condition. There is no known cure for this disorder.

Historical Perspective

Alport syndrome was first identified in a British family by Dr. Cecil A. Alport in 1927.

Pathophysiology

Genetics

Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 collagen biosynthesis genes. Mutations in any of these genes prevent the proper production or assembly of the type IV collagen network, which is an important structural component of the glomerular basement membranes in the kidney, inner ear, and eye.

This syndrome can have different inheritance patterns depending on the type of genetic mutation. In most people with the disorder, the condition is inherited in an X-linked pattern due to mutations in the COL4A5 gene. A condition is considered X-linked if the gene involved in the disorder is located on the X chromosome.

Alport syndrome can also be inherited in an autosomal recessive pattern if both copies of the COL4A3 or COL4A4 gene, located on chromosome 2, have been mutated. Most often, the parents of a child with an autosomal recessive disorder are not affected but are only carriers of one copy of the altered genes.

In males, who have only one X chromosome, one altered copy of the COL4A5 gene is sufficient to cause severe Alport syndrome. This single X chromosome explains why most affected males eventually develop chronic kidney failure. In females, who have two X chromosomes, a mutation in one copy of the COL4A5 gene usually results in blood in the urine, but most affected females do not develop kidney failure.

Associated Conditions

Some associated conditions that occur with Alport syndrome are chronic kidney failure, and proteinuria.

Microscopic Pathology

Basement membranes are thin, sheet-like structures that separate and support cells in many tissues. When mutations prevent the formation of type IV collagen fibers, the basement membranes of the kidneys are not able to filter waste products from the blood and create urine properly, which allows blood and protein to enter into the urine.

The abnormalities of type IV collagen in the glomerular basement membrane cause gradual scarring of the kidneys, eventually leading to chronic renal failure in many people with the disease.

Diagnosis

Diagnostic criteria

Gregory et al, 1996, give the following 10 criteria for the diagnosis of Alport syndrome [1]. 4 of the 10 criteria must be met for an accurate diagnosis:

Symptoms

Common symptoms of Alport syndrome include:

Physical Examination

Vital signs

Eyes

Fundoscopy shows:

  • Cataracts may be present
  • Subcapsular posterior lens opacities may be present
  • Lenticonus may be present
  • Retinal flecks (dot-and-fleck retinopathy) may be present
  • Posterior polymorphous corneal dystrophy/corneal epithelial erosions may be present

Ears

Extremities

Miscellaneous

Laboratory Findings

Urinalysis

Electrolytes and Metabolic disturbances

Biopsy Findings

Treatment

As there is no known cure for the condition, treatments are regimented for the symptoms of the condition.

Pharmacotherapy

Patients are advised on how to manage the complications of chronic kidney failure and the proteinuria that develops. Often, these symptoms are treated with ACE inhibitors, although they are not always used simply for the hypertension.

Surgery and Device Based Therapy

Once kidney failure has developed, patients undergo dialysis or may benefit from a kidney transplant, although this may result in rejection as the new kidney contains normal type IV collagen, which may be recognized as foreign by the immune system.

Future or Investigational Therapies

Gene therapy as a possible treatment option has been discussed. [2]

References

  1. Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996). "Alport syndrome--clinical phenotypes, incidence, and pathology". Contrib Nephrol. 117: 1–28. PMID 8801040.
  2. Tryggvason K, Heikkilä P, Pettersson E, Tibell A, Thorner P (1997). "Can Alport syndrome be treated by gene therapy?". Kidney Int. 51 (5): 1493–9. PMID 9150464. Unknown parameter |month= ignored (help)

This article incorporates public domain text from The U.S. National Library of Medicine

External links

Laboratory for Molecular Diagnostics, Center for Nephrology and Metabolic Disorders, Dr Mato Nagel

Template:Phakomatoses and other congenital malformations not elsewhere classified


Template:WS